Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Qiagen has submitted to the FDA its Therascreen EGFR RGQ PCR kit as a proposed companion diagnostic test to guide treatment with afatinib, an investigational oncology compound developed by Boehringer Ingelheim. The FDA has accepted afatinib for filing and granted it priority review as a proposed treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR mutation detected by an FDA-approved test.
Smart Imaging Technologies’ Simagis Live Web Pathology Platform version 4.0, launched last month, makes the transition to digital pathology simple and affordable. With Simagis cloud software, pathologists can connect scanners to a private cloud server and start collaborating.
Insight Genetics has received from the National Cancer Institute two small business innovation research contracts to continue its work developing diagnostic tests that identify and characterize specific genetic mutations in lung cancer patients.
Computype, in partnership with Nautilus Systems, launched the Flexible Tube and Vial Feeder (Flex TVF), a system for automatic downstream tube and vial feeding that increases efficiency.
Chembio Diagnostics has received FDA approval to market its point-of-care Dual Path Platform (DPP) HIV 1/2 assay for the rapid detection of HIV-1/2 antibodies in oral fluid or blood samples.
Akonni Biosystems recently announced results from three preclinical studies verifying the efficacy of its TruDiagnosis molecular diagnostic platform. Akonni TruArray tests are for mid-multiplex molecular diagnostics deployed in near point-of-care settings.
Cellular Engineering Technologies and the nonprofit John Paul II Medical Research Institute (JP2MRI) are partnering to develop a private stem cell biobank. The collaboration will create more than 5,000 patient- and disease-specific stem cell lines and other human cell lines to advance drug discovery and offer personalized medicine. These cell lines are derived from adult sources and do not include embryonic stem cells.
Luminex has received FDA clearance for its xTAG gastrointestinal pathogen panel (GPP), which is a comprehensive molecular diagnostic assay that tests for greater than 90 percent of bacterial, viral, and parasitic causes of infectious gastroenteritis.
DiaSorin has received FDA clearance for its Liaison direct renin immunoassay to aid in the diagnosis and treatment of certain types of hypertension.
AvanSci Bio has expanded its product line for dissecting slide-mounted tissue sections with its 2iD Scope and 2iD Cam for digital annotation of the areas to be dissected and xScision reagents for slide deparaffinization and dissection from paraffinized tissue sections. These new products, along with the company’s existing products for slide-mounted tissue mesodissection, provide a workflow solution capable of replacing manual slide-mounted tissue dissection for most pathology applications.
